

Leonidas C Platanias

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7056599/publications.pdf>

Version: 2024-02-01

237
papers

21,655
citations

17405

63
h-index

9839

141
g-index

239
all docs

239
docs citations

239
times ranked

35168
citing authors

#	ARTICLE	IF	CITATIONS
1	Abstract P2-02-05: Dynamic circulating tumor cell changes in enumeration and HER2 expression during systemic therapy for metastatic breast cancer. <i>Cancer Research</i> , 2022, 82, P2-02-05-P2-02-05.	0.4	0
2	Abstract PD14-01: Comprehensive molecular characterization of patients with metastatic invasive lobular carcinoma (ILC): Using <i>real-world</i> data to describe this unique clinical entity. <i>Cancer Research</i> , 2022, 82, PD14-01-PD14-01.	0.4	0
3	Abstract P2-01-04: Esr1 hotspot mutations in circulating tumor DNA mutation are associated with endocrine therapy resistance in metastatic breast cancer. <i>Cancer Research</i> , 2022, 82, P2-01-04-P2-01-04.	0.4	0
4	Abstract P2-01-08: <i>Esr1</i> Y537 mutations are associated with increased baseline circulating tumor cells enumeration for patients with estrogen receptor positive metastatic breast cancer. <i>Cancer Research</i> , 2022, 82, P2-01-08-P2-01-08.	0.4	0
5	Abstract P1-02-11: Somatic alterations and PD-L1 positivity in advanced breast cancer. <i>Cancer Research</i> , 2022, 82, P1-02-11-P1-02-11.	0.4	1
6	Discovery of a signaling feedback circuit that defines interferon responses in myeloproliferative neoplasms. <i>Nature Communications</i> , 2022, 13, 1750.	5.8	8
7	Cell-directed aptamer therapeutic targeting for cancers including those within the central nervous system. <i>Oncoimmunology</i> , 2022, 11, 2062827.	2.1	6
8	Regulation of IFN γ -induced expression of the short ACE2 isoform by ULK1. <i>Molecular Immunology</i> , 2022, 147, 1-9.	1.0	1
9	Outcomes of Cancer Patients with COVID-19 in a Hospital System in the Chicago Metropolitan Area. <i>Cancers</i> , 2022, 14, 2209.	1.7	2
10	Abstract LB117: Pilot study to identify live circulating tumor cells (CTCs) in metastatic breast cancer (MBC) by application of a novel microfluidic workflow system and flow cytometry. <i>Cancer Research</i> , 2022, 82, LB117-LB117.	0.4	0
11	Abstract 2548: The central nervous system immune cell interactome is a function of cancer lineage, tumor microenvironment and STAT3 expression. <i>Cancer Research</i> , 2022, 82, 2548-2548.	0.4	0
12	Genomic Landscape of Advanced Solid Tumors in Circulating Tumor DNA and Correlation With Tissue Sequencing: A Single Institution's Experience. <i>JCO Precision Oncology</i> , 2022, , .	1.5	9
13	Understanding the organ tropism of metastatic breast cancer through the combination of liquid biopsy tools. <i>European Journal of Cancer</i> , 2021, 143, 147-157.	1.3	32
14	Abstract PS2-08: Identification of incidental putative germline variants in circulating tumor DNA. , 2021, , .		0
15	Type I and II Interferons in the Anti-Tumor Immune Response. <i>Cancers</i> , 2021, 13, 1037.	1.7	47
16	Schlafen 5 as a novel therapeutic target in pancreatic ductal adenocarcinoma. <i>Oncogene</i> , 2021, 40, 3273-3286.	2.6	8
17	Inhibitory effects of Tomivosertib in acute myeloid leukemia. <i>Oncotarget</i> , 2021, 12, 955-966.	0.8	7
18	Longitudinal Dynamics of Circulating Tumor Cells and Circulating Tumor DNA for Treatment Monitoring in Metastatic Breast Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 943-952.	1.5	23

#	ARTICLE	IF	CITATIONS
19	Interferon maintenance for prevention of relapse in favorable risk AML?. <i>Leukemia and Lymphoma</i> , 2021, 62, 1-2.	0.6	0
20	Glioblastoma as an age-related neurological disorder in adults. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab125.	0.4	30
21	The Use of Serial Circulating Tumor DNA to Detect Resistance Alterations in Progressive Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 1361-1370.	3.2	25
22	Innate Immune Mechanisms and Immunotherapy of Myeloid Malignancies. <i>Biomedicines</i> , 2021, 9, 1631.	1.4	3
23	Performance of a novel Next Generation Sequencing circulating tumor DNA (ctDNA) platform for the evaluation of samples from patients with metastatic breast cancer (MBC). <i>Critical Reviews in Oncology/Hematology</i> , 2020, 145, 102856.	2.0	17
24	Type I Interferon (IFN)-Regulated Activation of Canonical and Non-Canonical Signaling Pathways. <i>Frontiers in Immunology</i> , 2020, 11, 606456.	2.2	98
25	Landscape of circulating tumour DNA in metastatic breast cancer. <i>EBioMedicine</i> , 2020, 58, 102914.	2.7	40
26	Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma. <i>Clinical Cancer Research</i> , 2020, 26, 5232-5245.	3.2	52
27	Hematological manifestations of COVID-19. <i>Leukemia and Lymphoma</i> , 2020, 61, 2790-2798.	0.6	30
28	An aberrantly sustained emergency granulopoiesis response accelerates postchemotherapy relapse in MLL1-rearranged acute myeloid leukemia in mice. <i>Journal of Biological Chemistry</i> , 2020, 295, 9663-9675.	1.6	2
29	Combined PI3K \pm -mTOR Targeting of Glioma Stem Cells. <i>Scientific Reports</i> , 2020, 10, 21873.	1.6	17
30	Impact of myosteatorsis in survivors of childhood acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2019, 60, 3097-3098.	0.6	1
31	Discovery of novel Mnk inhibitors using mutation \hat{c} based induced \hat{c} fit virtual high \hat{c} throughput screening. <i>Chemical Biology and Drug Design</i> , 2019, 94, 1813-1823.	1.5	7
32	Pharmacological mTOR targeting enhances the antineoplastic effects of selective PI3K \pm inhibition in medulloblastoma. <i>Scientific Reports</i> , 2019, 9, 12822.	1.6	24
33	Myeloid-Derived Suppressive Cells Promote B cell \hat{c} Mediated Immunosuppression via Transfer of PD-L1 in Glioblastoma. <i>Cancer Immunology Research</i> , 2019, 7, 1928-1943.	1.6	99
34	Natural killer cell activity and survival after azacitidine treatment in high-risk MDS. <i>Leukemia and Lymphoma</i> , 2019, 60, 2343-2344.	0.6	0
35	Potent Antineoplastic Effects of Combined PI3K \pm \hat{c} MNK Inhibition in Medulloblastoma. <i>Molecular Cancer Research</i> , 2019, 17, 1305-1315.	1.5	10
36	Interferon signaling in cancer. Non-canonical pathways and control of intracellular immune checkpoints. <i>Seminars in Immunology</i> , 2019, 43, 101299.	2.7	35

#	ARTICLE	IF	CITATIONS
37	Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer. <i>Breast Cancer Research</i> , 2019, 21, 137.	2.2	42
38	Identification and targeting of novel CDK9 complexes in acute myeloid leukemia. <i>Blood</i> , 2019, 133, 1171-1185.	0.6	26
39	Sirtuin 2-mediated deacetylation of cyclin-dependent kinase 9 promotes STAT1 signaling in type I interferon responses. <i>Journal of Biological Chemistry</i> , 2019, 294, 827-837.	1.6	24
40	Inhibitory effects of SEL201 in acute myeloid leukemia. <i>Oncotarget</i> , 2019, 10, 7112-7121.	0.8	12
41	The E3 ubiquitin ligase Triad1 influences development of Mll-Ell-induced acute myeloid leukemia. <i>Oncogene</i> , 2018, 37, 2532-2544.	2.6	14
42	IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma. <i>Clinical Cancer Research</i> , 2018, 24, 2559-2573.	3.2	147
43	HDL nanoparticles targeting sonic hedgehog subtype medulloblastoma. <i>Scientific Reports</i> , 2018, 8, 1211.	1.6	30
44	Transforming growth factor superfamily ligands and links to tumorigenesis. <i>Leukemia and Lymphoma</i> , 2018, 59, 1282-1283.	0.6	2
45	Implications of high EVI1 expression in high-risk myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , 2018, 59, 2765-2766.	0.6	0
46	Rapamycin Modulates Glucocorticoid Receptor Function, Blocks Atrophogene REDD1, and Protects Skin from Steroid Atrophy. <i>Journal of Investigative Dermatology</i> , 2018, 138, 1935-1944.	0.3	25
47	Differential Response of Glioma Stem Cells to Arsenic Trioxide Therapy Is Regulated by MNK1 and mRNA Translation. <i>Molecular Cancer Research</i> , 2018, 16, 32-46.	1.5	29
48	IFN- γ -inducible antiviral responses require ULK1-mediated activation of MLK3 and ERK5. <i>Science Signaling</i> , 2018, 11, .	1.6	17
49	Spontaneous remission in congenital leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 2271-2272.	0.6	3
50	Sfn2 Regulates Type I Interferon Responses by Modulating the NF- κ B Pathway. <i>Molecular and Cellular Biology</i> , 2018, 38, .	1.1	13
51	Circulating tumor cells enumeration (CTCs) and circulating tumor DNA (ctDNA): Clinical and molecular features of rapidly progressing stage IV disease (Stage IVprog).. <i>Journal of Clinical Oncology</i> , 2018, 36, 12040-12040.	0.8	0
52	Dual targeting of eIF4E by blocking MNK and mTOR pathways in leukemia. <i>Cytokine</i> , 2017, 89, 116-121.	1.4	29
53	Another tyrosine kinase inhibitor-resistance mutation within the BCR-ABL kinase domain: chasing our tails?. <i>Leukemia and Lymphoma</i> , 2017, 58, 1526-1527.	0.6	2
54	Central Regulatory Role for SIN1 in Interferon γ (IFN γ) Signaling and Generation of Biological Responses. <i>Journal of Biological Chemistry</i> , 2017, 292, 4743-4752.	1.6	6

#	ARTICLE	IF	CITATIONS
55	Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1412-1420.	1.9	114
56	Circulating microRNAs: promising biomarkers in aplastic anemia. <i>Haematologica</i> , 2017, 102, 1-2.	1.7	27
57	PD1 and PDL1 upregulation and survival after decitabine treatment in lower risk MDS. <i>Leukemia and Lymphoma</i> , 2017, 58, 764-765.	0.6	4
58	Concordance between genomic alterations assessed by next-generation sequencing in tumor tissue or circulating cell-free DNA. <i>Oncotarget</i> , 2016, 7, 65364-65373.	0.8	99
59	A simple, low-cost staining method for rapid-throughput analysis of tumor spheroids. <i>BioTechniques</i> , 2016, 60, 43-6.	0.8	11
60	MNK Inhibition Disrupts Mesenchymal Glioma Stem Cells and Prolongs Survival in a Mouse Model of Glioblastoma. <i>Molecular Cancer Research</i> , 2016, 14, 984-993.	1.5	38
61	Beyond autophagy: New roles for ULK1 in immune signaling and interferon responses. <i>Cytokine and Growth Factor Reviews</i> , 2016, 29, 17-22.	3.2	19
62	SNPing away to individualize induction therapy for acute myelogenous leukemia. <i>Leukemia and Lymphoma</i> , 2016, 57, 742-743.	0.6	0
63	Merestinib blocks Mnk kinase activity in acute myeloid leukemia progenitors and exhibits antileukemic effects in vitro and in vivo. <i>Blood</i> , 2016, 128, 410-414.	0.6	40
64	Discovery and characterization of novel small-molecule CXCR4 receptor agonists and antagonists. <i>Scientific Reports</i> , 2016, 6, 30155.	1.6	51
65	Targeting the mTOR Pathway in Leukemia. <i>Journal of Cellular Biochemistry</i> , 2016, 117, 1745-1752.	1.2	50
66	Pexmetinib: A Novel Dual Inhibitor of Tie2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid Leukemia. <i>Cancer Research</i> , 2016, 76, 4841-4849.	0.4	32
67	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016, 12, 1-222.	4.3	4,701
68	Differential Regulation of ZEB1 and EMT by MAPK-Interacting Protein Kinases (MNK) and eIF4E in Pancreatic Cancer. <i>Molecular Cancer Research</i> , 2016, 14, 216-227.	1.5	38
69	Evolving Therapeutic Strategies for the Classic Philadelphia-Negative Myeloproliferative Neoplasms. <i>EBioMedicine</i> , 2016, 3, 17-25.	2.7	6
70	Interferon \hat{I}^3 (IFN \hat{I}^3) Signaling via Mechanistic Target of Rapamycin Complex 2 (mTORC2) and Regulatory Effects in the Generation of Type II Interferon Biological Responses. <i>Journal of Biological Chemistry</i> , 2016, 291, 2389-2396.	1.6	25
71	Whole-exome sequencing for relapse prediction in patients discontinuing TKI treatment in chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2016, 57, 1503-1504.	0.6	1
72	The Interferon Consensus Sequence Binding Protein (Icsbp/Irf8) Is Required for Termination of Emergency Granulopoiesis. <i>Journal of Biological Chemistry</i> , 2016, 291, 4107-4120.	1.6	19

#	ARTICLE	IF	CITATIONS
73	Targeting of glioblastoma cell lines and glioma stem cells by combined PIM kinase and PI3K-p110 α inhibition. <i>Oncotarget</i> , 2016, 7, 33192-33201.	0.8	26
74	Mesenchymal stromal cells and interferon γ (IFN γ) in cancer immunotherapy. <i>Translational Cancer Research</i> , 2016, 5, S1039-S1043.	0.4	2
75	Human Schlafen 5 (SLFN5) Is a Regulator of Motility and Invasiveness of Renal Cell Carcinoma Cells. <i>Molecular and Cellular Biology</i> , 2015, 35, 2684-2698.	1.1	48
76	Direct Binding of Arsenic Trioxide to AMPK and Generation of Inhibitory Effects on Acute Myeloid Leukemia Precursors. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 202-212.	1.9	24
77	Central Role of ULK1 in Type I Interferon Signaling. <i>Cell Reports</i> , 2015, 11, 605-617.	2.9	66
78	Overcoming treatment challenges in imatinib-resistant chronic myelogenous leukemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 1581-1582.	0.6	0
79	IRF8 directs stress-induced autophagy in macrophages and promotes clearance of <i>Listeria monocytogenes</i> . <i>Nature Communications</i> , 2015, 6, 6379.	5.8	75
80	Targeting mTOR signaling pathways and related negative feedback loops for the treatment of acute myeloid leukemia. <i>Cancer Biology and Therapy</i> , 2015, 16, 648-656.	1.5	35
81	Rituximab and glucocorticoids: friends or foes? It is all about timing. <i>Leukemia and Lymphoma</i> , 2015, 56, 2237-2238.	0.6	0
82	Catalytic mammalian target of rapamycin inhibitors as antineoplastic agents. <i>Leukemia and Lymphoma</i> , 2015, 56, 2518-2523.	0.6	1
83	Synergism between arsenic trioxide and aclacinomycin in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 3010-3011.	0.6	0
84	Intersection of mTOR and STAT signaling in immunity. <i>Trends in Immunology</i> , 2015, 36, 21-29.	2.9	119
85	Pre-clinical evidence of PIM kinase inhibitor activity in BCR-ABL1 unmutated and mutated Philadelphia chromosome-positive (Ph+) leukemias. <i>Oncotarget</i> , 2015, 6, 33206-33216.	0.8	11
86	ULK1 in type I interferon response. <i>Oncotarget</i> , 2015, 6, 24586-24587.	0.8	3
87	The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression. <i>Oncotarget</i> , 2015, 6, 37930-37947.	0.8	32
88	Resveratrol enhances the suppressive effects of arsenic trioxide on primitive leukemic progenitors. <i>Cancer Biology and Therapy</i> , 2014, 15, 473-478.	1.5	14
89	Critical Roles for Rictor/Sin1 Complexes in Interferon-dependent Gene Transcription and Generation of Antiproliferative Responses. <i>Journal of Biological Chemistry</i> , 2014, 289, 6581-6591.	1.6	19
90	Pediatric acute lymphoblastic leukemia: the missing pieces in risk and survival. <i>Leukemia and Lymphoma</i> , 2014, 55, 2226-2227.	0.6	1

#	ARTICLE	IF	CITATIONS
91	Use of mTOR inhibitors in the treatment of malignancies. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 979-990.	0.9	5
92	Regulatory effects of SKAR in interferon $\hat{\pm}$ signaling and its role in the generation of type I IFN responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 11377-11382.	3.3	11
93	Autophagy Is a Survival Mechanism of Acute Myelogenous Leukemia Precursors during Dual mTORC2/mTORC1 Targeting. <i>Clinical Cancer Research</i> , 2014, 20, 2400-2409.	3.2	90
94	Interferon Receptor Signaling in Malignancy: A Network of Cellular Pathways Defining Biological Outcomes. <i>Molecular Cancer Research</i> , 2014, 12, 1691-1703.	1.5	77
95	Regulation of Interferon-Dependent mRNA Translation of Target Genes. <i>Journal of Interferon and Cytokine Research</i> , 2014, 34, 289-296.	0.5	30
96	New insights into malignant cell survival mechanisms in medulloblastoma. <i>Cancer Cell & Microenvironment</i> , 2014, 1, .	0.8	2
97	Regulatory effects of a Mnk2-eIF4E feedback loop during mTORC1 targeting of human medulloblastoma cells. <i>Oncotarget</i> , 2014, 5, 8442-8451.	0.8	35
98	Mnk kinase pathway: Cellular functions and biological outcomes. <i>World Journal of Biological Chemistry</i> , 2014, 5, 321.	1.7	129
99	IFN- $\hat{2}$ -specific signaling via a unique IFNAR1 interaction. <i>Nature Immunology</i> , 2013, 14, 884-885.	7.0	13
100	STAT Activation in Malignancies: Roles in Tumor Progression and in the Generation of Antineoplastic Effects of IFNs. <i>Journal of Interferon and Cytokine Research</i> , 2013, 33, 181-188.	0.5	7
101	Tyrosine kinase inhibition in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2013, 54, 1351-1352.	0.6	0
102	Antileukemic properties of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. <i>Leukemia and Lymphoma</i> , 2013, 54, 2601-2605.	0.6	13
103	Interferons and Their Antitumor Properties. <i>Journal of Interferon and Cytokine Research</i> , 2013, 33, 143-144.	0.5	20
104	The Schlafen Family of Proteins and Their Regulation by Interferons. <i>Journal of Interferon and Cytokine Research</i> , 2013, 33, 206-210.	0.5	131
105	Next generation of mammalian target of rapamycin inhibitors for the treatment of cancer. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 715-722.	1.9	16
106	Acute myeloid leukemia: potential for new therapeutic approaches targeting mRNA translation pathways. <i>International Journal of Hematologic Oncology</i> , 2013, 2, 243-250.	0.7	5
107	Expression and Regulatory Effects of Murine Schlafen (Slfn) Genes in Malignant Melanoma and Renal Cell Carcinoma. <i>Journal of Biological Chemistry</i> , 2013, 288, 33006-33015.	1.6	31
108	Essential Role for the Mnk Pathway in the Inhibitory Effects of Type I Interferons on Myeloproliferative Neoplasm (MPN) Precursors. <i>Journal of Biological Chemistry</i> , 2013, 288, 23814-23822.	1.6	16

#	ARTICLE	IF	CITATIONS
109	BCR-ABL1-induced leukemogenesis and autophagic targeting by arsenic trioxide. <i>Autophagy</i> , 2013, 9, 93-94.	4.3	15
110	Regulation of the kinase RSK1 by arsenic trioxide and generation of antileukemic responses. <i>Cancer Biology and Therapy</i> , 2013, 14, 411-416.	1.5	10
111	Inhibition of Mnk kinase activity by cercosporamide and suppressive effects on acute myeloid leukemia precursors. <i>Blood</i> , 2013, 121, 3675-3681.	0.6	88
112	Regulatory Effects of Sestrin 3 (SESN3) in BCR-ABL Expressing Cells. <i>PLoS ONE</i> , 2013, 8, e78780.	1.1	10
113	Sprouty Proteins Are Negative Regulators of Interferon (IFN) Signaling and IFN-inducible Biological Responses. <i>Journal of Biological Chemistry</i> , 2012, 287, 42352-42360.	1.6	36
114	Mnk kinases in cytokine signaling and regulation of cytokine responses. <i>Biomolecular Concepts</i> , 2012, 3, 127-139.	1.0	35
115	Regulatory effects of mTORC2 complexes in type I IFN signaling and in the generation of IFN responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 7723-7728.	3.3	46
116	Regulatory Effects of Programmed Cell Death 4 (PDCD4) Protein in Interferon (IFN)-Stimulated Gene Expression and Generation of Type I IFN Responses. <i>Molecular and Cellular Biology</i> , 2012, 32, 2809-2822.	1.1	23
117	Statin-dependent activation of protein kinase C δ in acute promyelocytic leukemia cells and induction of leukemic cell differentiation. <i>Leukemia and Lymphoma</i> , 2012, 53, 1779-1784.	0.6	13
118	An overview of the mTOR pathway as a target in cancer therapy. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, 481-489.	1.5	33
119	Autophagic degradation of the BCR-ABL oncoprotein and generation of antileukemic responses by arsenic trioxide. <i>Blood</i> , 2012, 120, 3555-3562.	0.6	117
120	Guidelines for the use and interpretation of assays for monitoring autophagy. <i>Autophagy</i> , 2012, 8, 445-544.	4.3	3,122
121	Targeting AMPK in the treatment of malignancies. <i>Journal of Cellular Biochemistry</i> , 2012, 113, 404-409.	1.2	34
122	Mechanisms of BCR-ABL leukemogenesis and novel targets for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2011, 52, 2-3.	0.6	3
123	Essential Role for Mnk Kinases in Type II Interferon (IFN γ) Signaling and Its Suppressive Effects on Normal Hematopoiesis. <i>Journal of Biological Chemistry</i> , 2011, 286, 6017-6026.	1.6	32
124	Regulation of mammalian target of rapamycin and mitogen activated protein kinase pathways by BCR-ABL. <i>Leukemia and Lymphoma</i> , 2011, 52, 45-53.	0.6	29
125	Emerging roles for mammalian target of rapamycin inhibitors in the treatment of solid tumors and hematological malignancies. <i>Current Opinion in Oncology</i> , 2011, 23, 578-586.	1.1	43
126	Antileukemic effects of AMPK activators on BCR-ABL-expressing cells. <i>Blood</i> , 2011, 118, 6399-6402.	0.6	74

#	ARTICLE	IF	CITATIONS
127	Antiviral Effects of Interferon- \hat{I}^2 are Enhanced in the Absence of the Translational Suppressor 4E-BP1 in Myocarditis Induced by Coxsackievirus B3. <i>Antiviral Therapy</i> , 2011, 16, 577-584.	0.6	13
128	Dual mTORC2/mTORC1 Targeting Results in Potent Suppressive Effects on Acute Myeloid Leukemia (AML) Progenitors. <i>Clinical Cancer Research</i> , 2011, 17, 4378-4388.	3.2	92
129	Protein Kinase R as Mediator of the Effects of Interferon (IFN) \hat{I}^3 and Tumor Necrosis Factor (TNF) \hat{I}^{\pm} on Normal and Dysplastic Hematopoiesis. <i>Journal of Biological Chemistry</i> , 2011, 286, 27506-27514.	1.6	25
130	Regulatory Effects of Ribosomal S6 Kinase 1 (RSK1) in IFN \hat{I}^{\pm} Signaling. <i>Journal of Biological Chemistry</i> , 2011, 286, 1147-1156.	1.6	17
131	Targeting mTOR for the treatment of AML. New agents and new directions. <i>Oncotarget</i> , 2011, 2, 510-517.	0.8	85
132	AMPK in BCR-ABL expressing leukemias. Regulatory effects and therapeutic implications. <i>Oncotarget</i> , 2011, 2, 1322-1328.	0.8	42
133	Statins. , 2011, , 3502-3503.		0
134	Abnormalities in Th17 T cells in aplastic anemia. <i>Blood</i> , 2010, 116, 4039-4040.	0.6	6
135	Arsenic Trioxide-Dependent Activation of Thousand-and-One Amino Acid Kinase 2 and Transforming Growth Factor- \hat{I}^2 -Activated Kinase 1. <i>Molecular Pharmacology</i> , 2010, 77, 828-835.	1.0	9
136	Role of Interferon \hat{I}^{\pm} (IFN \hat{I}^{\pm})-inducible Schlafen-5 in Regulation of Anchorage-independent Growth and Invasion of Malignant Melanoma Cells. <i>Journal of Biological Chemistry</i> , 2010, 285, 40333-40341.	1.6	78
137	Autophagy Is a Critical Mechanism for the Induction of the Antileukemic Effects of Arsenic Trioxide. <i>Journal of Biological Chemistry</i> , 2010, 285, 29989-29997.	1.6	110
138	Arsenic Trioxide and the Phosphoinositide 3-Kinase/Akt Pathway in Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2010, 16, 4311-4312.	3.2	20
139	Negative Regulatory Effects of Mnk Kinases in the Generation of Chemotherapy-Induced Antileukemic Responses. <i>Molecular Pharmacology</i> , 2010, 78, 778-784.	1.0	39
140	Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 12469-12474.	3.3	166
141	Induction of autophagy by dual mTORC1-mTORC2 inhibition in BCR-ABL-expressing leukemic cells. <i>Autophagy</i> , 2010, 6, 966-967.	4.3	19
142	AMPK as a therapeutic target in renal cell carcinoma. <i>Cancer Biology and Therapy</i> , 2010, 10, 1168-1177.	1.5	55
143	Deregulation of Interferon Signaling in Malignant Cells. <i>Pharmaceuticals</i> , 2010, 3, 406-418.	1.7	26
144	Mechanisms of mRNA translation of interferon stimulated genes. <i>Cytokine</i> , 2010, 52, 123-127.	1.4	43

#	ARTICLE	IF	CITATIONS
145	AMP-activated kinase (AMPK)-generated signals in malignant melanoma cell growth and survival. <i>Biochemical and Biophysical Research Communications</i> , 2010, 398, 135-139.	1.0	54
146	Prospects for mTOR targeting in adult T cell leukemia. <i>Leukemia and Lymphoma</i> , 2009, 50, 525-526.	0.6	1
147	Role of Schlafen 2 (SLFN2) in the Generation of Interferon $\hat{\pm}$ -induced Growth Inhibitory Responses. <i>Journal of Biological Chemistry</i> , 2009, 284, 25051-25064.	1.6	60
148	Interferon-Dependent Engagement of Eukaryotic Initiation Factor 4B via S6 Kinase (S6K)- and Ribosomal Protein S6K-Mediated Signals. <i>Molecular and Cellular Biology</i> , 2009, 29, 2865-2875.	1.1	62
149	Regulation of leukemic cell differentiation and retinoid-induced gene expression by statins. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 615-625.	1.9	14
150	Activation of the p38 Map kinase pathway is essential for the antileukemic effects of dasatinib. <i>Leukemia and Lymphoma</i> , 2009, 50, 2017-2029.	0.6	44
151	Activation of Protein Kinase C $\hat{\pm}$ by Type I Interferons. <i>Journal of Biological Chemistry</i> , 2009, 284, 10301-10314.	1.6	16
152	Type I interferon (IFN)-dependent activation of Mnk1 and its role in the generation of growth inhibitory responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 12097-12102.	3.3	79
153	Growth suppressive cytokines and the AKT/mTOR pathway. <i>Cytokine</i> , 2009, 48, 138-143.	1.4	26
154	Biological Responses to Arsenic Compounds. <i>Journal of Biological Chemistry</i> , 2009, 284, 18583-18587.	1.6	129
155	Glutathione Depletion Enhances Arsenic Trioxide-Induced Apoptosis in Lymphoma Cells through Mitochondrial and Caspase-Independent Mechanisms.. <i>Blood</i> , 2009, 114, 2708-2708.	0.6	1
156	Statins in tumor suppression. <i>Cancer Letters</i> , 2008, 260, 11-19.	3.2	156
157	Inhibition of p38 $\hat{\pm}$ MAPK disrupts the pathological loop of proinflammatory factor production in the myelodysplastic syndrome bone marrow microenvironment. <i>Leukemia and Lymphoma</i> , 2008, 49, 1963-1975.	0.6	32
158	Akt and mRNA translation by interferons. <i>Cell Cycle</i> , 2008, 7, 2112-2116.	1.3	28
159	Regulatory Effects of Mammalian Target of Rapamycin-mediated Signals in the Generation of Arsenic Trioxide Responses. <i>Journal of Biological Chemistry</i> , 2008, 283, 1992-2001.	1.6	40
160	Suppression of Programmed Cell Death 4 (PDCD4) Protein Expression by BCR-ABL-regulated Engagement of the mTOR/p70 S6 Kinase Pathway. <i>Journal of Biological Chemistry</i> , 2008, 283, 8601-8610.	1.6	65
161	Role of the Akt pathway in mRNA translation of interferon-stimulated genes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 4808-4813.	3.3	183
162	Regulation of Arsenic Trioxide-induced Cellular Responses by Mnk1 and Mnk2. <i>Journal of Biological Chemistry</i> , 2008, 283, 12034-12042.	1.6	35

#	ARTICLE	IF	CITATIONS
163	Statin-Dependent Suppression of the Akt/Mammalian Target of Rapamycin Signaling Cascade and Programmed Cell Death 4 Up-Regulation in Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2008, 14, 4640-4649.	3.2	64
164	Suppression of Interferon (IFN)-inducible Genes and IFN-mediated Functional Responses in BCR-ABL-expressing Cells. <i>Journal of Biological Chemistry</i> , 2008, 283, 10793-10803.	1.6	21
165	Protein kinase C signalling in leukemia. <i>Leukemia and Lymphoma</i> , 2008, 49, 1255-1262.	0.6	15
166	Dual Regulatory Roles of Phosphatidylinositol 3-Kinase in IFN Signaling. <i>Journal of Immunology</i> , 2008, 181, 7316-7323.	0.4	74
167	Exploiting the mammalian target of rapamycin pathway in hematologic malignancies. <i>Current Opinion in Hematology</i> , 2008, 15, 88-94.	1.2	32
168	Regulatory Effects of Mammalian Target of Rapamycin-activated Pathways in Type I and II Interferon Signaling. <i>Journal of Biological Chemistry</i> , 2007, 282, 1757-1768.	1.6	98
169	Suppressive Effects of Statins on Acute Promyelocytic Leukemia Cells. <i>Cancer Research</i> , 2007, 67, 4524-4532.	0.4	75
170	The Protein Kinase C (PKC) Family of Proteins in Cytokine Signaling in Hematopoiesis. <i>Journal of Interferon and Cytokine Research</i> , 2007, 27, 623-636.	0.5	45
171	MTHFR polymorphisms and the development of acute leukemia: Does it really matter?. <i>Leukemia and Lymphoma</i> , 2006, 47, 2002-2003.	0.6	2
172	Interferon-inducible genes and aplastic anemia. <i>Blood</i> , 2006, 107, 2-3.	0.6	1
173	Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors. <i>Blood</i> , 2006, 108, 4170-4177.	0.6	120
174	Role of the p38 Mitogen-Activated Protein Kinase Pathway in the Generation of Arsenic Trioxide-Dependent Cellular Responses. <i>Cancer Research</i> , 2006, 66, 6763-6771.	0.4	80
175	Activation of mammalian target of rapamycin and the p70 S6 kinase by arsenic trioxide in BCR-ABL-expressing cells. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 2815-2823.	1.9	24
176	Activation of the Mitogen- and Stress-activated Kinase 1 by Arsenic Trioxide. <i>Journal of Biological Chemistry</i> , 2006, 281, 22446-22452.	1.6	55
177	Targeting the mTOR Pathway Suppresses the Growth of Acute Myeloid Leukemia (AML) Progenitors and Enhances Arsenic Trioxide Induced Antileukemic Responses.. <i>Blood</i> , 2006, 108, 1898-1898.	0.6	0
178	Vitamin D and acute promyelocytic leukemia. <i>Leukemia and Lymphoma</i> , 2006, 47, 581.	0.6	0
179	Interferons. , 2005, 126, 45-68.		12
180	Genistein Inhibits p38 Map Kinase Activation, Matrix Metalloproteinase Type 2, and Cell Invasion in Human Prostate Epithelial Cells. <i>Cancer Research</i> , 2005, 65, 3470-3478.	0.4	201

#	ARTICLE	IF	CITATIONS
181	Activation of the p70 S6 kinase by all-trans-retinoic acid in acute promyelocytic leukemia cells. <i>Blood</i> , 2005, 105, 1669-1677.	0.6	46
182	Differential regulation of the p70 S6 kinase pathway by interferon $\hat{\pm}$ (IFN $\hat{\pm}$) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells. <i>Blood</i> , 2005, 106, 2436-2443.	0.6	57
183	Mechanisms of type-I- and type-II-interferon-mediated signalling. <i>Nature Reviews Immunology</i> , 2005, 5, 375-386.	10.6	2,758
184	Role of protein kinase C- $\hat{\gamma}$ (PKC- $\hat{\gamma}$) in the generation of the effects of IFN- $\hat{\pm}$ in chronic myelogenous leukemia cells. <i>Experimental Hematology</i> , 2005, 33, 550-557.	0.2	37
185	Activation of Mitogen-activated Protein Kinase Kinase (MKK) 3 and MKK6 by Type I Interferons. <i>Journal of Biological Chemistry</i> , 2005, 280, 10001-10010.	1.6	33
186	Introduction: Interferon Signals: What Is Classical and What Is Nonclassical?. <i>Journal of Interferon and Cytokine Research</i> , 2005, 25, 732-732.	0.5	30
187	The PI3' Kinase Pathway in Interferon Signaling. <i>Journal of Interferon and Cytokine Research</i> , 2005, 25, 780-787.	0.5	71
188	A Role for Mixed Lineage Kinases in Regulating Transcription Factor CCAAT/Enhancer-binding Protein- $\hat{2}$ -dependent Gene Expression in Response to Interferon- $\hat{3}$. <i>Journal of Biological Chemistry</i> , 2005, 280, 24462-24471.	1.6	21
189	Role of the p38 Mitogen-Activated Protein Kinase Pathway in Cytokine-Mediated Hematopoietic Suppression in Myelodysplastic Syndromes. <i>Cancer Research</i> , 2005, 65, 9029-9037.	0.4	60
190	The p38 Mitogen-Activated Protein Kinase Pathway in Interferon Signal Transduction. <i>Journal of Interferon and Cytokine Research</i> , 2005, 25, 749-756.	0.5	74
191	Role of p38 $\hat{\pm}$ Map Kinase in Type I Interferon Signaling. <i>Journal of Biological Chemistry</i> , 2004, 279, 970-979.	1.6	106
192	Differential Regulation of Membrane Type 1-Matrix Metalloproteinase Activity by ERK 1/2- and p38 MAPK-modulated Tissue Inhibitor of Metalloproteinases 2 Expression Controls Transforming Growth Factor- $\hat{2}$ 1-induced Pericellular Collagenolysis. <i>Journal of Biological Chemistry</i> , 2004, 279, 39042-39050.	1.6	130
193	Role of the p38 Mitogen-activated Protein Kinase Pathway in the Generation of the Effects of Imatinib Mesylate (STI571) in BCR-ABL-expressing Cells. <i>Journal of Biological Chemistry</i> , 2004, 279, 25345-25352.	1.6	63
194	Engagement of Protein Kinase C- $\hat{\gamma}$ in Interferon Signaling in T-cells. <i>Journal of Biological Chemistry</i> , 2004, 279, 29911-29920.	1.6	47
195	Signalling Pathways Activated by All-trans-Retinoic Acid in Acute Promyelocytic Leukemia Cells. <i>Leukemia and Lymphoma</i> , 2004, 45, 2175-2185.	0.6	26
196	Interferon- $\hat{3}$ engages the p70 S6 kinase to regulate phosphorylation of the 40S S6 ribosomal protein. <i>Experimental Cell Research</i> , 2004, 295, 173-182.	1.2	79
197	Mechanisms of Type-I Interferon Signal Transduction. <i>BMB Reports</i> , 2004, 37, 635-641.	1.1	36
198	Jak family of kinases in cancer. <i>Cancer and Metastasis Reviews</i> , 2003, 22, 423-434.	2.7	126

#	ARTICLE	IF	CITATIONS
199	The p38 mitogen-activated protein kinase pathway and its role in interferon signaling. , 2003, 98, 129-142.		134
200	Role of Stat5 in Type I interferon-signaling and transcriptional regulation. Biochemical and Biophysical Research Communications, 2003, 308, 325-330.	1.0	56
201	Activation of Protein Kinase C β by IFN γ . Journal of Immunology, 2003, 171, 267-273.	0.4	124
202	Activation of Protein Kinase C β by All-trans-retinoic Acid. Journal of Biological Chemistry, 2003, 278, 32544-32551.	1.6	101
203	Activation of the p70 S6 Kinase and Phosphorylation of the 4E-BP1 Repressor of mRNA Translation by Type I Interferons. Journal of Biological Chemistry, 2003, 278, 27772-27780.	1.6	114
204	Interferons: mechanisms of action and clinical applications. Current Opinion in Oncology, 2003, 15, 431-439.	1.1	166
205	Map kinase signaling pathways and hematologic malignancies. Blood, 2003, 101, 4667-4679.	0.6	389
206	Activation of the p38 Mitogen-activated Protein Kinase Mediates the Suppressive Effects of Type I Interferons and Transforming Growth Factor- β on Normal Hematopoiesis. Journal of Biological Chemistry, 2002, 277, 7726-7735.	1.6	153
207	Signaling Via the Interferon- α Receptor in Chronic Myelogenous Leukemia Cells. Leukemia and Lymphoma, 2002, 43, 703-709.	0.6	36
208	Activation of Rac1 and the p38 Mitogen-activated Protein Kinase Pathway in Response to Arsenic Trioxide. Journal of Biological Chemistry, 2002, 277, 44988-44995.	1.6	112
209	Cutting Edge: Activation of the p38 Mitogen-Activated Protein Kinase Signaling Pathway Mediates Cytokine-Induced Hemopoietic Suppression in Aplastic Anemia. Journal of Immunology, 2002, 168, 5984-5988.	0.4	93
210	MEKK1 plays a critical role in activating the transcription factor C/EBP- β -dependent gene expression in response to IFN- α . Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 7945-7950.	3.3	88
211	Protein Kinase C β (PKC- β) Is Activated by Type I Interferons and Mediates Phosphorylation of Stat1 on Serine 727. Journal of Biological Chemistry, 2002, 277, 14408-14416.	1.6	193
212	The CrkL Adapter Protein Is Required for Type I Interferon-Dependent Gene Transcription and Activation of the Small G-Protein Rap1. Biochemical and Biophysical Research Communications, 2002, 291, 744-750.	1.0	36
213	Engagement of the CrkL adaptor in interferon α signalling in BCR-ABL-expressing cells. British Journal of Haematology, 2001, 112, 327-336.	1.2	35
214	ERK1 and ERK2 Activate CCAAAT/Enhancer-binding Protein- β -dependent Gene Transcription in Response to Interferon- β . Journal of Biological Chemistry, 2001, 276, 287-297.	1.6	151
215	The p38 MAPK Pathway Mediates the Growth Inhibitory Effects of Interferon- α in BCR-ABL-expressing Cells. Journal of Biological Chemistry, 2001, 276, 28570-28577.	1.6	135
216	Activation of Rac1 and the p38 Mitogen-activated Protein Kinase Pathway in Response to All-trans-retinoic Acid. Journal of Biological Chemistry, 2001, 276, 4012-4019.	1.6	146

#	ARTICLE	IF	CITATIONS
217	IFN- β Activates the C3G/Rap1 Signaling Pathway. <i>Journal of Immunology</i> , 2000, 164, 1800-1806.	0.4	68
218	The Rac1/p38 Mitogen-activated Protein Kinase Pathway Is Required for Interferon β -dependent Transcriptional Activation but Not Serine Phosphorylation of Stat Proteins. <i>Journal of Biological Chemistry</i> , 2000, 275, 27634-27640.	1.6	175
219	Engagement of the CrkL Adapter in Interleukin-5 Signaling in Eosinophils. <i>Journal of Biological Chemistry</i> , 2000, 275, 33167-33175.	1.6	26
220	Interferon-Dependent Activation of the Serine Kinase PI 3 β -Kinase Requires Engagement of the IRS Pathway but Not the Stat Pathway. <i>Biochemical and Biophysical Research Communications</i> , 2000, 270, 158-162.	1.0	66
221	The Proximal Tyrosines of the Cytoplasmic Domain of the β Chain of the Type I Interferon Receptor Are Essential for Signal Transducer and Activator of Transcription (Stat) 2 Activation. <i>Journal of Biological Chemistry</i> , 1999, 274, 4045-4052.	1.6	48
222	Activation of the p38 Mitogen-activated Protein Kinase by Type I Interferons. <i>Journal of Biological Chemistry</i> , 1999, 274, 30127-30131.	1.6	211
223	Engagement of Gab1 and Gab2 in Erythropoietin Signaling. <i>Journal of Biological Chemistry</i> , 1999, 274, 24469-24474.	1.6	88
224	Activation of a CrkL-Stat5 Signaling Complex by Type I Interferons. <i>Journal of Biological Chemistry</i> , 1999, 274, 571-573.	1.6	120
225	CrkL and CrkII participate in the generation of the growth inhibitory effects of interferons on primary hematopoietic progenitors. <i>Experimental Hematology</i> , 1999, 27, 1315-1321.	0.2	56
226	Interferon β activates the tyrosine kinase Lyn in haemopoietic cells. <i>British Journal of Haematology</i> , 1998, 101, 446-449.	1.2	13
227	The Type I Interferon Receptor Mediates Tyrosine Phosphorylation of the CrkL Adaptor Protein. <i>Journal of Biological Chemistry</i> , 1997, 272, 29991-29994.	1.6	91
228	The vav proto-oncogene product (p95 vav) interacts with the Tyk-2 protein tyrosine kinase. <i>FEBS Letters</i> , 1997, 403, 31-34.	1.3	33
229	Differences in Interferon β and γ Signaling. <i>Journal of Biological Chemistry</i> , 1996, 271, 23630-23633.	1.6	89
230	The Type I Interferon Receptor Mediates Tyrosine Phosphorylation of Insulin Receptor Substrate 2. <i>Journal of Biological Chemistry</i> , 1996, 271, 278-282.	1.6	113
231	Interferons. <i>Current Opinion in Oncology</i> , 1995, 7, 560-565.	1.1	36
232	Association of the Interferon-dependent Tyrosine Kinase Tyk-2 with the Hematopoietic Cell Phosphatase. <i>Journal of Biological Chemistry</i> , 1995, 270, 18179-18182.	1.6	108
233	Interferon- β Engages the Insulin Receptor Substrate-1 to Associate with the Phosphatidylinositol 3 β -Kinase. <i>Journal of Biological Chemistry</i> , 1995, 270, 15938-15941.	1.6	177
234	Interaction of the Transcriptional Activator Stat-2 with the Type I Interferon Receptor. <i>Journal of Biological Chemistry</i> , 1995, 270, 24627-24630.	1.6	40

#	ARTICLE	IF	CITATIONS
235	Expression of the IFN γ receptor in hairy cell leukaemia. <i>British Journal of Haematology</i> , 1992, 82, 541-546.	1.2	16
236	Hairy cell leukaemia: The role of alpha interferon. <i>European Journal of Cancer & Clinical Oncology</i> , 1991, 27, S53-S57.	0.9	5
237	Relapse of Hodgkin's Disease After 14 Years of Complete Remission. <i>Leukemia and Lymphoma</i> , 1990, 3, 223-226.	0.6	4